SERA Insider Transactions
| Transaction Date (SEC Report ) |
Reporting Name | Relationship | Shrs. Owned | Type | Acq./Disp. | Shrs. Transacted | Price() | Amount() |
|---|---|---|---|---|---|---|---|---|
| 2023-03-07 | CRITCHFIELD GREGORY C | director, officer: Chief Executive Officer | 98,300 | A-Award | A | 98,300 | 3.72 | 365,676.00 |
| 2023-03-07 | CRITCHFIELD GREGORY C | director, officer: Chief Executive Officer | 857,145 | A-Award | A | 62,200 | 0.00 | 0.00 |
| 2023-03-06 | Foley Michael R | officer: Chief Medical Officer | 42,700 | A-Award | A | 42,700 | 3.80 | 162,260.00 |
| 2023-03-06 | Foley Michael R | officer: Chief Medical Officer | 27,000 | A-Award | A | 27,000 | 0.00 | 0.00 |
| 2023-03-06 | Altomare Nadia | officer: Chief Commercial Officer | 28,900 | A-Award | A | 28,900 | 3.80 | 109,820.00 |
| 2023-03-06 | Altomare Nadia | officer: Chief Commercial Officer | 18,300 | A-Award | A | 18,300 | 0.00 | 0.00 |
| 2023-03-06 | Kearney Paul | officer: Chief Data Officer | 25,300 | A-Award | A | 25,300 | 3.80 | 96,140.00 |
| 2023-03-06 | Kearney Paul | officer: Chief Data Officer | 16,000 | A-Award | A | 16,000 | 0.00 | 0.00 |
| 2023-03-06 | Boniface John J. | officer: Chief Scientific Officer | 34,900 | A-Award | A | 34,900 | 3.80 | 132,620.00 |
| 2023-03-06 | Boniface John J. | officer: Chief Scientific Officer | 69,454 | A-Award | A | 22,100 | 0.00 | 0.00 |
| 2023-03-06 | MOYES JAY M | officer: Chief Financial Officer | 51,800 | A-Award | A | 51,800 | 3.80 | 196,840.00 |
| 2023-03-06 | MOYES JAY M | officer: Chief Financial Officer | 35,630 | A-Award | A | 32,800 | 0.00 | 0.00 |
| 2023-03-06 | Jackson Benjamin | officer: General Counsel | 39,100 | A-Award | A | 39,100 | 3.80 | 148,580.00 |
| 2023-03-06 | Jackson Benjamin | officer: General Counsel | 32,700 | A-Award | A | 24,700 | 0.00 | 0.00 |
| 2023-03-06 | Harrison Robert Gardner | officer: Chief Information Officer | 45,000 | A-Award | A | 45,000 | 3.80 | 171,000.00 |
| 2023-03-06 | Harrison Robert Gardner | officer: Chief Information Officer | 28,500 | A-Award | A | 28,500 | 0.00 | 0.00 |
| 2022-09-08 | Boniface John J. | officer: Chief Scientific Officer | 0 | M-Exempt | D | 844 | 0.73 | 616.12 |
| 2022-09-08 | Boniface John J. | officer: Chief Scientific Officer | 47,354 | M-Exempt | A | 844 | 0.73 | 616.12 |
| 2022-07-27 | Boniface John J. | officer: Chief Scientific Officer | 844 | M-Exempt | D | 1,000 | 0.73 | 730.00 |
| 2022-07-27 | Boniface John J. | officer: Chief Scientific Officer | 46,510 | S-Sale | D | 1,000 | 2.22 | 2,220.00 |
| 2022-07-27 | Boniface John J. | officer: Chief Scientific Officer | 47,510 | M-Exempt | A | 1,000 | 0.73 | 730.00 |
| 2022-07-26 | Boniface John J. | officer: Chief Scientific Officer | 46,510 | S-Sale | D | 2,725 | 2.15 | 5,858.75 |
| 2022-07-19 | Boniface John J. | officer: Chief Scientific Officer | 49,235 | S-Sale | D | 2,725 | 1.86 | 5,068.50 |
| 2022-07-18 | Blue Ox Healthcare Partners, LLC | 10 percent owner | 46,744 | J-Other | D | 1,157,764 | 0.00 | 0.00 |
| 2022-07-18 | Blue Ox Healthcare Partners, LLC | 10 percent owner | 77,420 | J-Other | D | 997,627 | 0.00 | 0.00 |
| 2022-07-18 | Blue Ox Healthcare Partners, LLC | 10 percent owner | 132,501 | J-Other | D | 1,383,094 | 0.00 | 0.00 |
| 2022-07-12 | Boniface John J. | officer: Chief Scientific Officer | 51,960 | S-Sale | D | 2,725 | 1.84 | 5,014.00 |
| 2022-07-05 | Boniface John J. | officer: Chief Scientific Officer | 54,685 | S-Sale | D | 2,725 | 1.63 | 4,441.75 |
| 2022-06-29 | Boniface John J. | officer: Chief Scientific Officer | 1,844 | M-Exempt | D | 1,000 | 0.73 | 730.00 |
| 2022-06-29 | Boniface John J. | officer: Chief Scientific Officer | 57,410 | S-Sale | D | 1,000 | 1.72 | 1,720.00 |
| 2022-06-29 | Boniface John J. | officer: Chief Scientific Officer | 58,410 | M-Exempt | A | 1,000 | 0.73 | 730.00 |
| 2022-06-28 | Boniface John J. | officer: Chief Scientific Officer | 57,410 | S-Sale | D | 2,725 | 1.89 | 5,150.25 |
| 2022-06-21 | Boniface John J. | officer: Chief Scientific Officer | 60,135 | S-Sale | D | 2,725 | 1.31 | 3,569.75 |
| 2022-06-14 | Boniface John J. | officer: Chief Scientific Officer | 62,860 | S-Sale | D | 2,725 | 1.21 | 3,297.25 |
| 2022-06-14 | Jackson Benjamin | officer: General Counsel | 8,000 | P-Purchase | A | 8,000 | 1.20 | 9,600.00 |
| 2022-06-07 | Boniface John J. | officer: Chief Scientific Officer | 65,585 | S-Sale | D | 2,725 | 1.30 | 3,542.50 |
| 2022-06-03 | Lawrence Sandra AJ | director | 149,675 | A-Award | A | 149,675 | 1.35 | 202,061.25 |
| 2022-06-03 | Phillips Joshua | director | 149,675 | A-Award | A | 149,675 | 1.35 | 202,061.25 |
| 2022-06-03 | Mirza Mansoor Raza | director | 149,675 | A-Award | A | 149,675 | 1.35 | 202,061.25 |
| 2022-06-03 | Kamdar Kim P. | director | 149,675 | A-Award | A | 149,675 | 1.35 | 202,061.25 |
| 2022-06-03 | Lindgardt Zhenya | director | 149,675 | A-Award | A | 149,675 | 1.35 | 202,061.25 |
| 2022-06-03 | Trimble Ryan | director | 149,675 | A-Award | A | 149,675 | 1.35 | 202,061.25 |
| 2022-06-01 | Boniface John J. | officer: Chief Scientific Officer | 2,844 | M-Exempt | D | 1,000 | 0.73 | 730.00 |
| 2022-06-01 | Boniface John J. | officer: Chief Scientific Officer | 68,310 | S-Sale | D | 1,000 | 1.36 | 1,360.00 |
| 2022-06-01 | Boniface John J. | officer: Chief Scientific Officer | 69,310 | M-Exempt | A | 1,000 | 0.73 | 730.00 |
| 2022-05-31 | Boniface John J. | officer: Chief Scientific Officer | 68,310 | S-Sale | D | 2,725 | 1.45 | 3,951.25 |
| 2022-05-24 | Boniface John J. | officer: Chief Scientific Officer | 71,035 | S-Sale | D | 2,725 | 1.54 | 4,196.50 |
| 2022-05-17 | Boniface John J. | officer: Chief Scientific Officer | 73,760 | S-Sale | D | 2,725 | 1.55 | 4,223.75 |
| 2022-05-10 | Boniface John J. | officer: Chief Scientific Officer | 76,485 | S-Sale | D | 2,725 | 1.97 | 5,368.25 |
| 2022-05-04 | Boniface John J. | officer: Chief Scientific Officer | 3,844 | M-Exempt | D | 1,000 | 0.73 | 730.00 |
| 2022-05-04 | Boniface John J. | officer: Chief Scientific Officer | 79,210 | S-Sale | D | 1,000 | 2.17 | 2,170.00 |
| 2022-05-04 | Boniface John J. | officer: Chief Scientific Officer | 80,210 | M-Exempt | A | 1,000 | 0.73 | 730.00 |
| 2022-05-03 | Boniface John J. | officer: Chief Scientific Officer | 79,210 | S-Sale | D | 2,725 | 2.17 | 5,913.25 |
| 2022-04-26 | Boniface John J. | officer: Chief Scientific Officer | 81,935 | S-Sale | D | 2,725 | 2.17 | 5,913.25 |
| 2022-04-19 | Boniface John J. | officer: Chief Scientific Officer | 84,660 | S-Sale | D | 2,725 | 2.08 | 5,668.00 |
| 2022-04-12 | Boniface John J. | officer: Chief Scientific Officer | 87,385 | S-Sale | D | 2,725 | 2.66 | 7,248.50 |
| 2022-04-11 | Barlow Jane F | director | 140,823 | A-Award | A | 140,823 | 2.83 | 398,529.09 |
| 2022-04-06 | Boniface John J. | officer: Chief Scientific Officer | 4,844 | M-Exempt | D | 1,000 | 0.73 | 730.00 |
| 2022-04-06 | Boniface John J. | officer: Chief Scientific Officer | 90,110 | S-Sale | D | 1,000 | 3.02 | 3,020.00 |
| 2022-04-06 | Boniface John J. | officer: Chief Scientific Officer | 91,110 | M-Exempt | A | 1,000 | 0.73 | 730.00 |
| 2022-04-05 | Boniface John J. | officer: Chief Scientific Officer | 90,110 | S-Sale | D | 2,725 | 3.35 | 9,128.75 |
| 2022-03-29 | Boniface John J. | officer: Chief Scientific Officer | 92,835 | S-Sale | D | 2,725 | 3.73 | 10,164.25 |
| 2022-03-23 | Jackson Benjamin | officer: General Counsel | 60,345 | A-Award | A | 60,345 | 3.75 | 226,293.75 |
| 2022-03-23 | CRITCHFIELD GREGORY C | director, officer: Chief Executive Officer | 429,225 | A-Award | A | 429,225 | 3.75 | 1,609,593.75 |
| 2022-03-23 | Kearney Paul | officer: Chief Data Officer | 30,426 | A-Award | A | 30,426 | 3.75 | 114,097.50 |
| 2022-03-23 | MOYES JAY M | officer: Chief Financial Officer | 168,275 | A-Award | A | 168,275 | 3.75 | 631,031.25 |
| 2022-03-23 | Boniface John J. | officer: Chief Scientific Officer | 121,705 | A-Award | A | 121,705 | 3.75 | 456,393.75 |
| 2022-03-23 | Harrison Robert Gardner | officer: Chief Information Officer | 33,698 | A-Award | A | 33,698 | 3.75 | 126,367.50 |
| 2022-03-23 | Altomare Nadia | officer: Chief Commercial Officer | 75,735 | A-Award | A | 75,735 | 3.75 | 284,006.25 |
| 2022-03-22 | Boniface John J. | officer: Chief Scientific Officer | 95,560 | S-Sale | D | 2,725 | 3.68 | 10,028.00 |
| 2022-03-14 | Boniface John J. | officer: Chief Scientific Officer | 98,285 | S-Sale | D | 2,725 | 3.94 | 10,736.50 |
| 2022-03-11 | Boniface John J. | officer: Chief Scientific Officer | 0 | M-Exempt | D | 75,998 | 0.73 | 55,478.54 |
| 2022-03-11 | Boniface John J. | officer: Chief Scientific Officer | 101,010 | M-Exempt | A | 75,998 | 0.73 | 55,478.54 |
| 2022-01-28 | Foley Michael R | officer: Chief Medical Officer | 276,000 | A-Award | A | 276,000 | 6.59 | 1,818,840.00 |
| 2021-12-06 | Boniface John J. | officer: Chief Scientific Officer | 0 | M-Exempt | D | 25,012 | 0.73 | 18,258.76 |
| 2021-12-06 | Boniface John J. | officer: Chief Scientific Officer | 25,012 | M-Exempt | A | 25,012 | 0.73 | 18,258.76 |
| 2021-11-29 | Lawrence Sandra AJ | director | 40,332 | A-Award | A | 40,332 | 10.41 | 419,856.12 |
| 2021-11-08 | Lindgardt Zhenya | director | 38,325 | A-Award | A | 38,325 | 10.92 | 418,509.00 |
| 2021-11-01 | Kearney Paul | officer: Chief Data Officer | 107,000 | A-Award | A | 107,000 | 10.33 | 1,105,310.00 |
| 2021-08-26 | Garite Thomas | officer: VP, Clinical Sciences | 10,000 | A-Award | A | 10,000 | 9.95 | 99,500.00 |
| 2021-07-19 | Phillips Joshua | director | 0 | C-Conversion | D | 3,713 | 0.00 | 0.00 |
| 2021-07-19 | Phillips Joshua | director | 0 | C-Conversion | D | 3,713 | 0.00 | 0.00 |
| 2021-07-19 | Phillips Joshua | director | 0 | C-Conversion | D | 3,713 | 0.00 | 0.00 |
| 2021-07-19 | Phillips Joshua | director | 0 | C-Conversion | D | 3,713 | 0.00 | 0.00 |
| 2021-07-19 | Phillips Joshua | director | 0 | C-Conversion | D | 3,713 | 0.00 | 0.00 |
| 2021-07-19 | Phillips Joshua | director | 0 | C-Conversion | D | 3,713 | 0.00 | 0.00 |
| 2021-07-19 | Phillips Joshua | director | 0 | C-Conversion | D | 3,713 | 0.00 | 0.00 |
| 2021-07-19 | Phillips Joshua | director | 965,111 | C-Conversion | A | 3,713 | 0.00 | 0.00 |
| 2021-07-19 | Phillips Joshua | director | 961,398 | C-Conversion | A | 32,335 | 0.00 | 0.00 |
| 2021-07-19 | Phillips Joshua | director | 929,063 | C-Conversion | A | 160,601 | 0.00 | 0.00 |
| 2021-07-19 | Phillips Joshua | director | 768,462 | C-Conversion | A | 39,116 | 0.00 | 0.00 |
| 2021-07-19 | Phillips Joshua | director | 729,346 | C-Conversion | A | 47,857 | 0.00 | 0.00 |
| 2021-07-19 | Phillips Joshua | director | 681,489 | C-Conversion | A | 85,577 | 0.00 | 0.00 |
| 2021-07-19 | Phillips Joshua | director | 595,912 | C-Conversion | A | 41,193 | 0.00 | 0.00 |
| 2021-07-19 | Phillips Joshua | director | 554,719 | C-Conversion | A | 166,098 | 0.00 | 0.00 |
| 2021-07-19 | Phillips Joshua | director | 388,621 | C-Conversion | A | 24,942 | 0.00 | 0.00 |
| 2021-07-19 | Phillips Joshua | director | 363,679 | C-Conversion | A | 34,030 | 0.00 | 0.00 |
| 2021-07-19 | Phillips Joshua | director | 329,649 | C-Conversion | A | 19,240 | 0.00 | 0.00 |
| 2021-07-19 | Phillips Joshua | director | 310,409 | C-Conversion | A | 231,678 | 0.00 | 0.00 |
| 2021-07-19 | Phillips Joshua | director | 78,731 | C-Conversion | A | 41,182 | 0.00 | 0.00 |
Disclaimer: The data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by our third party API www.financialmodellingprep.com, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore, Discounting Cash Flows Group doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Discounting Cash Flows Group or anyone involved with Discounting Cash Flows Group will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.